Psilocybin & Magic Mushrooms

Oregon Dropped Its Psilocybin Fee Hike After Licensees Said They Would Walk

The Oregon Health Authority wanted $20,000 annual licenses. Community surveys suggested enough licensees would quit that the state would collect less than it does today.

An MDMA Course Takes 34 Clinician Hours Per Patient

Israeli MDMA trials run 15 sessions over three to four months, including an eight hour dosing day with two therapists present. The staffing math is the part US clinics should be reading.

The First Psilocybin Clinics Will Probably Be Spravato Clinics

Virginia passed a trigger law for FDA-approved psilocybin, and both Compass Pathways and Journey Clinical plan to launch at existing Spravato sites.

The Only Two Placebo-Controlled Microdosing Trials Found Nothing

A systematic review screened 897 references on psilocybin microdosing. Of 11 studies, only two were placebo controlled, and neither found a benefit.

Psilocybin Protected Nerves From Chemo in Mice. A Non-Hallucinogenic Version Worked Too

A Science paper found psilocybin prevented chemotherapy nerve damage in mice across six treatment cycles. A non-hallucinogenic compound did the same.

A High THC Dose Felt Like Psilocybin. The Study Had Four People

A Johns Hopkins pilot reported 25 mg of THC produced a psilocybin-like experience. It enrolled four participants and was funded by a cannabis foundation.

The Case That Psychedelics Sometimes Make Thinking Less Flexible

Cognitive flexibility is the standard explanation for how psychedelics work. A new review argues the acute effect may sometimes run the other way.

New Mexico Just Opened Its First Psilocybin Permits. The One Clinicians Need Is Still Coming

New Mexico began accepting psilocybin producer applications on August 17. The clinician permit has not opened, and the end of 2026 target looks unlikely.

Every Psychedelic Company Is Racing to Get the Patient Out of the Chair Faster

Lilly paid up to $3.8 billion for a compound whose selling point is a two hour clinic visit. Session length, not efficacy, is now the axis that separates psychedelic programs.

Oregon Tracks Psilocybin Safety for Three Days. The New Data Found Problems at Three Months

A JAMA Network Open study followed 346 people through Oregon's licensed psilocybin program. The adverse events showed up long after the state stops looking.